Welcome to our dedicated page for Scilex Holding Company SEC filings (Ticker: SCLXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company SEC filings page for the warrant symbol SCLXW provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Scilex’s common stock (SCLX) and its warrants to purchase common stock at an exercise price of $402.50 per share (SCLXW) are listed on The Nasdaq Stock Market LLC, and the company identifies itself as an emerging growth company in its reports.
Through forms such as Form 10-K, Form 10-Q, and Form S-1, Scilex describes its business of acquiring, developing, and commercializing non-opioid pain management products, including commercial products ZTlido ae, ELYXYB ae, and Gloperba ae, and product candidates SP-102, SP-103, and SP-104. The registration statement on Form S-1 specifically addresses aspects of the company’s warrants and related securities offerings.
Current reports on Form 8-K give detail on material events that may be relevant to SCLXW holders, such as warrant exchange agreements, new warrant issuances, equity lines of credit, and options to repurchase previously issued warrants. For example, Scilex has reported a Common Stock Purchase Agreement with an institutional investor, Warrant Exchange Agreements that modify existing warrant terms, and an option agreement with Oramed Pharmaceuticals Inc. to repurchase penny warrants. Other 8-K filings discuss Semnur Pharmaceuticals, Inc.’s merger agreement with Denali Capital Acquisition Corp. and changes in executive leadership.
These filings also disclose Scilex’s collaborations and licensing arrangements, including a worldwide exclusive license from Datavault AI Inc. for AI-driven tokenization technology in biotech and biopharma, and strategic investments in Datavault AI. Such agreements can influence Scilex’s long-term business model and potential revenue sources, and are documented in detail in the underlying exhibits and narrative sections.
On Stock Titan, investors can use AI-powered tools to review Scilex’s 10-K annual reports, 10-Q quarterly reports, S-1 registration statements, and 8-K current reports. AI-generated summaries help explain complex capital structure terms for SCLXW, highlight key risk factors and business descriptions, and surface notable items such as warrant terms, exchange ratios, and major financing arrangements, while real-time updates ensure new EDGAR filings are reflected promptly.
Scilex Holding Co director and CFO Stephen Hoi Ma reported an open-market purchase of 650,000 warrants. Each warrant was bought at $0.1538 and gives the right to buy one share of common stock at an exercise price of $1.20 per share.
The warrants were acquired on April 17, 2026 and are scheduled to expire on June 18, 2029. Following this transaction, Ma holds 650,000 warrants, each exercisable for one share of Scilex common stock.
Scilex Holding Co executive Henry Ji reported mixed warrant trades. On April 16, 2026, he made an open-market purchase of 3,250,000 warrants at $0.1538 per warrant, each exercisable at $1.20 for common stock. On April 17, 2026, he sold 650,000 warrants at the same price, leaving 2,600,000 warrants held directly, expiring on June 18, 2029.
Scilex Holding Company filed a Form S-3 to register up to $500,000,000 of securities on a shelf. The shelf prospectus permits offers of common stock, preferred stock, debt securities, warrants, rights and units in one or more offerings. The document describes existing commercial products (ZTlido, ELYXYB, GLOPERBA), pipeline assets (SP-102, SP-103, SP-104), certain corporate history and governance provisions, and states proceeds are intended for working capital and general corporate purposes.
Scilex Holding Company reports on a business focused on non-opioid pain management while outlining a major shift in its balance sheet strategy toward cryptocurrencies. The company currently markets three U.S. products: ZTlido for postherpetic neuralgia, ELYXYB for acute migraine, and GLOPERBA for prophylaxis of gout flares.
Its pipeline includes SEMDEXA (SP-102) for sciatica, SP-103 for acute low back and neck pain, and SP-104 for fibromyalgia, several with FDA fast track designations or completed Phase 3 or Phase 2 studies. Scilex also plans to adopt a cryptocurrency treasury strategy emphasizing bitcoin, Ethereum, BNB, Doge and similar assets as a principal long-term reserve, using third-party custodians and advisors, and potentially raising capital specifically to expand these holdings.
Scilex Holding Company entered into a Warrant Agreement with Oramed Pharmaceuticals under which Oramed deferred an amortization payment on Scilex’s Tranche B senior secured convertible note that had been scheduled for October 1, 2025. In exchange, Scilex agreed to issue Oramed a new warrant to purchase 100,000 shares of common stock at an initial exercise price of $20.00 per share, called the February 2026 Warrant. The deferred amortization payment was ultimately made in November 2025, and the warrant is immediately exercisable and expires on December 13, 2029.
Scilex committed to file a registration statement to register the resale by Oramed of the shares issuable upon exercise, or to include them in another Form S-3. The warrant includes price-adjustment mechanisms, subject to a floor of $8.22 per share, a beneficial ownership cap initially at 4.99% (optionally adjustable up to 9.99% with notice), cashless exercise if no effective registration is available, and change-of-control protections allowing Oramed to require cash repurchase based on Black Scholes value.
Scilex Holding Company’s Schedule 13G/A Amendment No. 4 reports that Oramed Pharmaceuticals Inc. beneficially owns 437,510 shares of Scilex common stock, representing 4.9% of the outstanding class. These shares are issuable upon exercise of warrants and conversion of convertible notes that are exercisable within 60 days.
The ownership percentage is calculated using 8,491,267 Scilex common shares outstanding as of December 5, 2025, plus the 437,510 shares underlying Oramed’s instruments. Oramed states the securities were not acquired and are not held for the purpose of changing or influencing control of Scilex.
Scilex Holding Company announced that its board of directors has revoked a previously declared stock dividend of 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock. This preferred stock had been authorized but no shares were ever issued.
In connection with the revocation, Scilex filed a Certificate of Elimination in Delaware, which became effective upon filing. This action eliminated the Series 1 designation and returned the 5,000,000 preferred shares to the company’s pool of undesignated preferred stock, effectively ending the special series that had been created for the contemplated dividend.
Scilex Holding Company entered into a financing and equity transaction with Quantum Scan Holdings, Inc. (Q Scan). Scilex loaned Q Scan $20 million under a convertible promissory note dated January 29, 2026, which fully converted that same day into 140,379,226 shares of Q Scan common stock.
Separately, Scilex agreed in a common stock purchase agreement to buy an additional 193,021,436 Q Scan shares for an aggregate price of approximately $27.5 million, with closing to occur within five business days after Q Scan delivers written notice. Scilex’s Chief Financial Officer, Stephen Ma, has served as Q Scan’s interim CFO since January 16, 2026 and, as of this report, has not received compensation from Q Scan in that role.
Scilex Holding Company disclosed changes in executive status and debtor-in-possession (DIP) financing arrangements. Dr. Ji is referenced in connection with a decision to resign as Chief Executive Officer and President to focus on Semnur, while the filing also states his compensation was not changed upon appointment as CEO and President and that he entered an indemnification agreement. The filing compares terms of a Junior DIP Loan (higher interest and fees: 14.0% vs 12.0%, maturity 5 vs 3 months, commitment/funding fees 2.5% vs 1.0%, exit fee 7.0% vs 2.0%). It describes a $100,000,000 Replacement DIP Facility provided by Oramed Pharmaceuticals, which refinanced the Senior DIP and included milestones and a lender credit-bid right for collateral (including equity interests). The Purchase Price for certain assets included a cash payment of $10,000,000 and assumption of approximately $12.25 million in legal fees; Sorrento retained 54,777 common shares in abeyance. A Pay-Off Letter would terminate the Junior DIP Loan Agreement and related security agreements upon Closing.